Discovery of 5-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-N-(tert-butyl)pyridine-3-sulfonamide (CZC24758), as a potent, orally bioavailable and selective inhibitor of PI3K for the treatment of inflammatory disease

被引：23
|
作者：
Sunose, Mihiro [1 ]
Bell, Kathryn [1 ]
Ellard, Katie [1 ]
Bergamini, Giovanna [2 ]
Neubauer, Gitte [2 ]
Werner, Thilo [2 ]
Ramsden, Nigel [1 ]
机构：
[1] Cellzome Ltd, Saffron Walden CB10 1XL, England
[2] Cellzome AG, D-69117 Heidelberg, Germany
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2012年 / 22卷 / 14期
关键词：
PI3K gamma; Inflammation; Triazolopyridine; Collagen induced arthritis; Rheumatoid arthritis; PHOSPHOINOSITIDE 3-KINASE PATHWAY; RHEUMATOID-ARTHRITIS; PI3K-GAMMA; CANCER; ACTIVATION; ISOFORM; KINASE; GAMMA;
D O I：
10.1016/j.bmcl.2012.05.090
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Herein, we disclose the discovery of a series of 7-substituted triazolopyridines which culminated in the identification of 14 (CZC24758), a potent, orally bioavailable small-molecule inhibitor of PI3K gamma, an attractive drug target for inflammatory and autoimmune disorders. Compound 14 has excellent selectivity across the kinome, demonstrates good potency in cell based assays and furthermore exhibits in vivo efficacy in a collagen induced arthritis model in mouse after oral dosing. (C) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：4613 / 4618
页数：6
相关论文
共 50 条
  • [21] Discovery of N-[2-[5-[amino(imino)methyl]-2-hydroxyphenoxy]-3,5-difluoro-6-[3-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenoxy]pyridin-4-yl]-N-methylglycine (ZK-807834):: A potent, selective, and orally active inhibitor of the blood coagulation enzyme factor Xa
    Phillips, GB
    Buckman, BO
    Davey, DD
    Eagen, KA
    Guilford, WJ
    Hinchman, J
    Ho, E
    Koovakkat, S
    Liang, A
    Light, DR
    Mohan, R
    Ng, HP
    Post, JM
    Shaw, KJ
    Smith, D
    Subramanyam, B
    Sullivan, ME
    Trinh, L
    Vergona, R
    Walters, J
    White, K
    Whitlow, M
    Wu, S
    Xu, W
    Morrissey, MM
    JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (19) : 3557 - 3562
  • [22] Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor
    Quan, ML
    Lam, PYS
    Han, Q
    Pinto, DJP
    He, MY
    Li, RH
    Ellis, CD
    Clark, CG
    Teleha, CA
    Sun, JH
    Alexander, RS
    Bai, S
    Luettgen, JM
    Knabb, RM
    Wong, PC
    Wexler, RR
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (06) : 1729 - 1744
  • [23] The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor
    Goldberg, Frederick W.
    Finlay, M. Raymond, V
    Ting, Attilla K. T.
    Beattie, David
    Lamont, Gillian M.
    Fallan, Charlene
    Wrigley, Gail L.
    Schimpl, Marianne
    Howard, Martin R.
    Williamson, Beth
    Vazquez-Chantada, Mercedes
    Barratt, Derek G.
    Davies, Barry R.
    Cadogan, Elaine B.
    Ramos-Montoya, Antonio
    Dean, Emma
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (07) : 3461 - 3471
  • [24] 5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
    Beaufils, Florent
    Cmiljanovic, Natasa
    Cmiljanovic, Vladimir
    Bohnacker, Thomas
    Melone, Anna
    Marone, Romina
    Jackson, Eileen
    Zhang, Xuxiao
    Sele, Alexander
    Borsari, Chiara
    Mestan, Jurgen
    Hebeisen, Paul
    Hillmann, Petra
    Giese, Bernd
    Zvelebil, Marketa
    Fabbro, Doriano
    Williams, Roger L.
    Rageot, Denise
    Wymann, Matthias P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2017, 60 (17) : 7524 - 7538
  • [25] (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase
    Rageot, Denise
    Bohnacker, Thomas
    Keles, Erhan
    McPhail, Jacob A.
    Hoffmann, Reece M.
    Melone, Anna
    Borsari, Chiara
    Sriramaratnam, Rohitha
    Sele, Alexander M.
    Beaufils, Florent
    Hebeisen, Paul
    Fabbro, Doriano
    Hillmann, Petra
    Burke, John E.
    Wymann, Matthias P.
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (13) : 6241 - 6261
  • [26] Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor
    Su, Qibin
    Banks, Erica
    Bebernitz, Geraldine
    Bell, Kirsten
    Borenstein, Cassandra F.
    Chen, Huawei
    Chuaqui, Claudio E.
    Deng, Nanhua
    Ferguson, Andrew D.
    Kawatkar, Sameer
    Grimster, Neil P.
    Ruston, Linette
    Lyne, Paul D.
    Read, Jon A.
    Peng, Xianyou
    Pei, Xiaohui
    Fawell, Stephen
    Tang, Zhanlei
    Throner, Scott
    Vasbinder, Melissa M.
    Wang, Haoyu
    Winter-Holt, Jon
    Woessner, Richard
    Wu, Allan
    Yang, Wenzhan
    Zinda, Michael
    Kettle, Jason G.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (09) : 4517 - 4527
  • [27] Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H-pyran-4-yl)benzamide (GW788388):: A potent, selective, and orally active transforming growth factor-β type I receptor inhibitor
    Gellibert, F
    de Gouville, AC
    Woolven, J
    Mathews, N
    Nguyen, VL
    Bertho-Ruault, C
    Patikis, A
    Grygielko, ET
    Laping, NJ
    Huet, S
    JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (07) : 2210 - 2221
  • [28] Discovery of ((S)-5-(Methoxymethyl)-7-(1-methyl-1H-indol-2-yl)-2-(trifluoromethyl)-4,7-dihydropyrazolo[1,5-a]pyrimidin-6-yl)((S)-2-(3-methylisoxazol-5-yl)pyrrolidin-1-yl)methanone As a Potent and Selective IKur Inhibitor (vol 55, pg 3036, 2012)
    Finlay, Heather J.
    Lloyd, John
    Vaccaro, Wayne
    Kover, Alexander
    Yan, Lin
    Bhave, Gauri
    Prol, Joseph
    Tram Huynh
    Bhandaru, Rao
    Caringal, Yolanda
    DiMarco, John
    Gan, Jinping
    Harper, Tim
    Huang, Christine
    Conder, Mary Lee
    Sun, Huabin
    Levesque, Paul
    Blanar, Michael
    Atwal, Karnail
    Wexler, Ruth
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (17) : 7133 - 7133
  • [29] Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-2′- (methylsulfonyl)-[1,1′-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa
    Pinto, DJP
    Orwat, MJ
    Wang, SG
    Fevig, JM
    Quan, ML
    Amparo, E
    Cacciola, J
    Rossi, KA
    Alexander, RS
    Smallwood, AM
    Luettgen, JM
    Liang, L
    Aungst, BJ
    Wright, MR
    Knabb, RM
    Wong, PC
    Wexler, RR
    Lam, PYS
    JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (04) : 566 - 578
  • [30] Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N[3-fluoro-2′-(aminosulfonyl)[1,1′-biphenyl)1-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor
    Pruitt, JR
    Pinto, DJP
    Galemmo, RA
    Alexander, RS
    Rossi, KA
    Wells, BL
    Drummond, S
    Bostrom, LL
    Burdick, D
    Bruckner, R
    Chen, HY
    Smallwood, A
    Wong, PC
    Wright, MR
    Bai, S
    Luettgen, JM
    Knabb, RM
    Lam, PYS
    Wexler, RR
    JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (25) : 5298 - 5315
12345